<DOC>
	<DOCNO>NCT00004340</DOCNO>
	<brief_summary>OBJECTIVES : I . Evaluate separate combine skeletal effect recombinant human growth hormone ( GH ) calcitriol patient adynamic renal osteodystrophy . II . Assess whether calcium-regulated change parathyroid hormone secretion predict change bone formation . III . Characterize response GH cancellous bone growth plate cartilage patient secondary hyperparathyroidism calcitriol therapy .</brief_summary>
	<brief_title>Phase II Randomized Study Effects Growth Hormone Children Adolescents Maintenance Dialysis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize study . Patients stratify bone lesion turnover secondary hyperparathyroidism . Patients first group treat recombinant human growth hormone subcutaneously every day 8 month . Patients second group treat calcitriol 8 month , administer daily oral dose intraperitoneal dose three time week . Patients third group treat growth hormone calcitriol ( dosage ) . A control group receive hormonal therapy .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Osteodystrophy</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Endstage renal disease undergo continuous cycle peritoneal dialysis University California Los Angeles Prior/Concurrent Therapy No concurrent prednisone No concurrent cytotoxic agent At least 12 month since parathyroidectomy Patient Characteristics Other : No documented history poor compliance medical treatment regimen</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2002</verification_date>
	<keyword>end stage renal disease</keyword>
	<keyword>rare disease</keyword>
	<keyword>renal genitourinary disorder</keyword>
	<keyword>renal osteodystrophy</keyword>
</DOC>